• Explore /
  • Poster
  • / IMMUTACE: A biomarker-orientated phase II, single-arm, open-label AIO study of transarterial chemoembolization (TACE) in combination with nivolumab performed for intermediate-stage hepatocellular carcinoma (HCC; AIO-HEP-0217)—Updated efficacy results.

IMMUTACE: A biomarker-orientated phase II, single-arm, open-label AIO study of transarterial chemoembolization (TACE) in combination with nivolumab performed for intermediate-stage hepatocellular carcinoma (HCC; AIO-HEP-0217)—Updated efficacy results.

Abstract Poster

Authors

null

Anna Saborowski

Hannover Medical School, Hanover, Germany

Anna Saborowski , Dirk Waldschmidt , Jan Hinrichs , Thomas Jens Ettrich , Uwe Marc Martens , Ardian Mekolli , Enrico N De Toni , Thomas Berg , Michael Geißler , Guido Hausner , Martin Maenz , Ursula Ehmer , Marta Kirstein , Arndt Vogel

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Hepatobiliary Cancer

Clinical Trial Registration Number

NCT03572582

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 4116)

DOI

10.1200/JCO.2022.40.16_suppl.4116

Abstract #

4116

Poster Bd #

102

Abstract Disclosures

Similar Posters

First Author: Guoliang Shao

First Author: Xiang Nong

First Author: Hui Zeng

First Author: Tingbo Liang